A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Taiwan University Hospital
With
Merck Sharp & Dohme LLC
Age
16–35
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Men and women age ranged from 16\~35 who have anterior cruciate ligament injury and/or associated injuries are scheduled for ACL reconstruction surgery.
2. Patient agrees to participate into this study and is willing to sign the patient informed consent form.
Clareo Health | A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction
